Septerna downgraded by Wells Fargo with a new price target
$SEPN
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | $26.00 | Buy | H.C. Wainwright |
| 2/18/2025 | $14.00 | Overweight → Equal Weight | Wells Fargo |
| 11/19/2024 | $38.00 | Overweight | Analyst |
| 11/19/2024 | Buy | TD Cowen | |
| 11/19/2024 | $43.00 | Overweight | Wells Fargo |
| 11/19/2024 | $50.00 | Overweight | Cantor Fitzgerald |
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a.m. ET Live webcasts of the presentations will be available in the investors section of the company's website at www.septerna.com. Replays will be archived for at least 30 days f
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyna
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the second quarter ended June 30, 2025. "We are executing effectively across our portfolio, with each program nearing important milestones," said Je
H.C. Wainwright initiated coverage of Septerna with a rating of Buy and set a new price target of $26.00
Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00
Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
10-Q - Septerna, Inc. (0001984086) (Filer)
SC 13D - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins